Prevention Strategy of Chemotherapy-Induced Nausea and Vomiting (CINV) with Olanzapine: Alternative Option
DOI:
https://doi.org/10.38035/ijam.v1i3.70Keywords:
Chemotherapy, Nausea, Olanzapine, Prevention, VomitingAbstract
Chemotherapy-induced nausea and vomiting (CINV) is a major problem for patients who use chemotherapy and can lower the quality of life for many cancer patients. If the patient is continuing chemotherapy treatment, then the patient can be certain to experience CINV. Current CINV prevention strategies primarily use 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), dexamethasone, and/or neurokinin-1 receptor antagonists (NK-1 RAs). However, these preventive therapies have not been fully implemented, especially the use of NK-1 RAs because of the high cost. In addition, a standard therapy for CINV prevention is still not effective in controlling CINV symptoms. One alternative CINV preventive therapy option is to use olanzapine. It is an antipsychotic drug that can be used as a preventive therapy for CINV off-label. The purpose of this study is to explain the utilization of olanzapine as alternative choice of antiemetic therapy in preventing CINV.
References
Piko B, and Bassam A. Treatment of Tumor Therapy-Induced Nausea and Vomiting. Magyar Onkologia. 2009; 53(1): 39-45.
Burke TA, Wisniewski T, Ernst FR. Resource Utilization and Costs Associated with Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly or Moderately Emetogenic Chemotherapy Administered in The US Outpatient Hospital Setting. Supportive Care in Cancer. 2011;19(1): 131-140.
Russo S, Cinausero M, Gerratana L, Bozza C, Iacono D, Driol P, et al. Factors Affecting Patient's Perception of Anticancer Treatments Side‐Effects: An Observational Study. Expert Opinion on Drug Safety. 2014; 13(2): 139‐150.
Molassiotis A, Saunders M, Valle J, Wilson G, Lorigan P, Wardley A, et al. A Prospective Observational Study of Chemotherapy-Related Nausea and Vomiting in Routine Practice in A UK Cancer Centre. Supportive Care in Cancer. 2008; 16(2): 201-208.
Dinis J, Wisniewski T, Moreira A, Raposo J, Ma L, Burke TA. Chemotherapy-Induced Nausea and Vomiting in Portugal: Incidence versus Healthcare Provider Estimations and Effect on Quality of Life. Therapy. 2009; 6(4): 595-602.
Hawkins R, and Grunberg S. Chemotherapy-Induced Nausea and Vomiting: Challenges and Opportunities for Improved Patient Outcomes. Clinical Journal of Oncology Nursing. 2009; 13(1): 54-64.
Perwitasari DA, Mustofa M, Atthobari J, Dwiprahasto I. Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients with Gynecologic Cancer. International Journal of Gynecological Cancer. 2011; 22(1): 139-145.
Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on Daily Functioning and Indirect/Direct Costs Associated with Chemotherapy-Induced Nausea and Vomiting (CINV) in A US Population. Supportive Care in Cancer. 2011; 19(6): 843-851.
Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. Editors. Pharmacotherapy Principle & Practice. United States: McGraw-Hill Education. 2016; 4th Ed: pp. 323-324
Rao KV, Faso A. Chemotherapy-Induced Nausea and Vomiting: Optimizing Prevention and Management. American Health and Drug Benefits. 2012; 5(4): 232-240.
Herrstedt J, Rapoport B, Warr D, Roila F, Rittenberg C, Hesketh PJ. Acute Emesis: Moderately Emetogenic Chemotherapy. Supportive Care in Cancer. 2011; 19(1): 15-23.
Kawecki A, and Krzakowski M. Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting. Oncology in Clinical Practice. 2018; 14(2): 53-61.
Aapro M, Jordan K, Feyer P. Pathophysiology and Classification of Chemotherapy-Induced Nausea and Vomiting. In: Aapro M, Jordan K, Feyer P, eds. Prevention of Nausea and Vomiting in Cancer Patients. UK: Springer Healthcare Ltd. 2015; pp. 5-14.
Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. Efficacy of Olanzapine for The Prophylaxis and Rescue of Chemotherapy-Induced Nausea and Vomiting (CINV): A Systematic Review and Meta-Analysis. Supportive Care in Cancer. 2016; 24(5): 2381-2392.
Chelkeba L, Gidey K, Mamo A, Yohannes B, Matso T, Melaku T. Olanzapine for Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-Analysis. Pharmacy Practice. 2017; 15(1): 877.
Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y. Efficacy of Olanzapine for The Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: A Meta Analysis. British Journal of Clinical Pharmacology. 2017; 83: 1369-1379.
Martel ML, Klein LR, Rivard RL, Cole JB. A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department. Academic Emergency Medicine. 2016; 23(1): 29-35.
Malhotra K, Vu P, Wang DH, Lai H, Faziola LR. Olanzapine-Induced Neutropenia. Mental Illness. 2015; 7(1): 5871.
Schatzberg A. and Nemeroff C. The American Psychiatric Association Publishing Textbook of Psychopharmacology. United State: American Psychiatric Association Publishing. 2017; 5th Ed.
DrugBank. Olanzapine. Available at: https://www.drugbank.ca/drugs/DB00334. Accessed Mar 03, 2020.
Brafford MV, and Glode A. Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting. Journal of The Advanced Practitioner in Oncology. 2014; 5: 24-29.
Hocking CM, and Kichenadasse G. Olanzapine for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. Supportive Care in Cancer. 2014; 22: 1143-1151.
Navari RM. Olanzapine for The Prevention and Treatment of Chronic Nausea and Chemotherapy-Induced Nausea and Vomiting. European Journal of Pharmacology. 2014; 722: 180-186.
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor Binding Profile of The Atypical Antipsychotic Olanzapine. Neuropsychopharmacology. 1996; 14(2): 87-96.
Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as An Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer. Journal of Pain Symptom Management. 2003; 25(6): 578-582.
Licup N, and Baumrucker S. Olanzapine for Nausea and Vomiting. American Journal of Hospice and Palliative Medicine. 2010; 27(6): 432-434.
Al-Quteimat O, Tollison J, Siddiqui MA. Olanzapine for Prevention or Management of Chemotherapy-Induced Nausea and Vomiting: A Promising Option. Journal of Hematology Oncology Pharmacy. 2019; 9(1): 9-15.
DeRemer DL, Clemmons AB, Orr J, Clark SM, Gandhi AS. Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting. Pharmacotherapy. 2016; 36(2): 218-229.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: Pharmacokinetic and Pharmacodynamic Profile. Clinical Pharmacokinetics. 1999; 37(3): 177-193.
Chue P, and Singer P. A Review of Olanzapine-Associated Toxicity and Fatality in Overdose. Journal of Psychiatry and Neuroscience. 2003; 28(4): 253-261.
Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, et al. Disposition and Biotransformation of The Antipsychotic Agent Olanzapine in Humans. Drug Metabolism and Disposition. 1997; 25: 81-93.
Na Takuathung M, Hanprasertpong N, Teekachunhatean S, Koonrungsesomboon N. Impact of CYP1A2 Genetic Polymorphisms on Pharmacokinetics of Antipsychotic Drugs: A Systematic Review and Meta-Analysis. Acta Psychiatrica Scandinavica. 2019; 139(1): 15-25.
Prommer E. Olanzapine: Palliative Medicine Update. American Journal of Hospice and Palliative Medicine. 2013; 30(1): 75‐82
Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics. 2018; 57(12): 1493-1528.
Passik SD, Navari RM, Jung S-H, Nagy C, Vinson J, Kirsh KL, et al. A Phase I Trial of Olanzapine (Zyprexa) for The Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study. Cancer Investigation. 2004; 22: 383-388.
Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D. Clinical Research of Olanzapine for Prevention of Chemotherapy-Induced Nausea and Vomiting. Journal of Experimental and Clinical Cancer Research. 2009; 28: 131.
Lv YL, Liu W, Du YJ, Feng L, Wang YD, Wang L. Antiemetic Effect of Low Dose Olanzapine in Solid Tumor Chemotherapy. Chinese Journal of Cancer Prevention and Treatment. 2013; 20: 544-554.
Wang X, Wang L, Wang H, Zhang H. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-Small Cell Lung Cancer. Cell Biochemistry and Biophysics. 2015; 72(2): 471-473.
Wang W, Lou G, Zhang Y. Olanzapine with Ondansetron and Dexamethasone for The Prevention of Cisplatin-Based Chemotherapy-Induced Nausea and Vomiting in Lung Cancer. Medicine. 2018; 97: 1-6.
Meng Q, Chen GH, Guo PM. Olanzapine Combined with Normal Antiemetic Drugs in Patients on Solid Tumor Chemotherapy: Antiemetic Effect and Impact on Quality of Life. World Chinese Journal of Digestology. 2016; 24: 1117-1123.
James E, Drisya PM, Jose WM. Olanzapine Combined with Standard Antiemetic Regiments for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Single-Center Experience for South India. Asian Journal of Pharmaceutical and Clinical Research. 2017; 10(11): 247-251.
Mukhopadhyay S, Kwatra G, Alice KP, Badyal D. Role of Olanzapine in Chemotherapy-Induced Nausea and Vomiting on Platinum-based Chemotherapy Patients: A Randomized Controlled Study. Supportive Care in Cancer. 2017; 25(1): 145-154
Osman AAM, Elhassan MMA, AbdElrahim BHA, Ahmed FHA, Yousif JBH, Ahmed MAM, et al. Olanzapine for The Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study from Sudan. Journal of Global Oncology. 2018; 4: 1-9.
Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, Yamakage M. Olanzapine for The Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Pain Symptom and Management. 2014; 47(3): 542-550.
Navari RM, and Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine. 2016; 374(14): 1356-1367.
Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) versus FOND plus Olanzapine (FOND-O) for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 2018; 24: 2065-2071.
Saldanha SC, Dassapa L, Jacob LA, Babu SM, Lokesh KN, Rudresha AH, et al. Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy. Annals of Oncology. 2019; 30(5): v722.
Jeon SY, Han HS, Bae WK, Park MR, Shim H, Lee SC, et al. A Randomized, Double-Blind, Placebo-Controlled Study of The Safety and Efficacy of Olanzapine for The Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of The Korean South West Oncology Group (KSWOG) Study. Cancer Research and Treatment. 2019; 51(1): 90-97.
Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-nguansai S, Payapwattanawong S, Laohavinij S, et al. A Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy of Combination Olanzapine, Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Doxorubicin plus Cyclophosphamide. American Journal of Hospice and Palliative Medicine. 2019; 8(4): 372-380.
Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, et al. Efficacy and Safety of Olanzapine Combined with Aprepitant, Palonosetron, and Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin-Based Chemotherapy in Gynecological Cancer: KCOG-G1301 Phase II trial. Supportive Care in Cancer. 2016;24(2):675-682.
Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, et al. A Phase II Study of Palonosetron, Aprepitant, Dexamethasone and Olanzapine for The Prevention of Cisplatin-Based Chemotherapy-Induced Nausea and Vomiting in Patients with Thoracic Malignancy. Japanese Journal of Clinical Oncology. 2017; 47(9): 840-843.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus Standard Antiemetic Therapy for The Prevention of Chemotherapy-Induced Nausea and Vomiting (J-FORCE): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology. 2020; 21(2): 242-249.
Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, et al. Efficacy and Safety of 5 mg Olanzapine Combined with Aprepitant, Granisetron and Dexamethasone to Prevent Carboplatin-Induced Nausea and Vomiting in Patients with Gynecologic Cancer: A Multi-Institution Phase II Study. 2020; 156(3): 629-635.
Mukhopadhyay S, Dutta P, Bhattacharya B, Banerjee S, Biswas S, Mukhopadhyay-Samanta B. Low Dose vs. Standard Dose Adjuvant Olanzapine in Chemotherapy Induced Nausea and Vomiting: A Prospective, Randomized, Double Blinded, Controlled Study. Clinical Therapeutics. 2017; 39(8): E17.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, et al. A Double-Blind Randomized Phase II Dose-Finding Study of Olanzapine 10 mg or 5 mg for The Prophylaxis of Emesis Induced by Highly Emetogenic Cisplatin-Based Chemotherapy. International Journal of Clinical Oncology. 2018; 23(2): 382-388.
Chiu L, Chiu N, Chow R, Zhang L, Pasetka M, Stinson J, et al. Olanzapine for The Prophylaxis and Rescue of Chemotherapy-Induced Nausea and Vomiting (CINV): A Retrospective Study. American Journal of Hospice and Palliative Medicine. 2016; 5(3): 172-178.
Navari RM, Einhorn LH, Loehrer PJ, Sr., Passik SD, Vinson J, McClean J, et al. A Phase II Trial of Olanzapine, Dexamethasone, and Palonosetron for The Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study. Supportive Care in Cancer. 2007; 15: 1285-1291.
Shumway N, Terrazzino S, Jones C. A Randomized Pilot Study Comparing Aprepitant to Olanzapine for Treatment of Chemotherapy-Induced Nausea and Vomiting. ASCO Annual Meeting Proceedings 2009. http://meetinglibrary.asco.org/content/30941-65. Accessed Mar 12, 2020.
Navari RM, Gray SE, Kerr AC. Olanzapine versus Aprepitant for The Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial. The Journal of Supportive Oncology. 2011; 9(5): 188-195.
Shumway NM, Terrazzino SE, Jones CB. A Randomized Pilot Study Comparing Olanzapine (Zyprexa) to Aprepitant (Emend) for Treatment of Chemotherapy-Induced Nausea and Vomiting. Journal of Pain Management. 2015; 8: 233-241.
Babu G, Saldanha SC, Kuntegowdanahalli L, Jacob LA, Mallekavu SB, Dasappa L, et al. The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India. Chemotherapy Research and Practice. 2016; 2016: 3439707.
Navari R, Nagy C, Le-Rademacher J, Loprinzi C. Olanzapine versus Fosaprepitant for The Prevention of Concurrent Chemotherapy Radiotherapy-Induced Nausea and Vomiting. Journal of Community Supportive and Oncology. 2016; 14(4): 141-147.
Trifilio S, Welles C, Seeger K, Mehta S, Fishman M, McGowan K, et al. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia. 2017; 17(9): 584-589.
Akshay JK, and Basavanna OL. Cost-Effectiveness of Newer Anti-Emesis in The Prevention of Chemotherapy Induced Nausea and Vomiting: A Pharmaco-economic Study Analysis. International Journal of Basic and Clinical Pharmacology. 2018; 7(6): 1141-1146.
Chanthawong S, Lim YH, Subongkot S, Chan A, Andalusia R, Bustamam RS, et al. Cost‐Effectiveness Analysis of Olanzapine‐Containing Antiemetic Therapy for Managing Highly Emetogenic Chemotherapy in Southeast Asia: A Multinational Study. Supportive Care in Cancer 2019; 27: 1109‐1119.
Dhanushkodi M. Olanzapine: The Game-Changer “Antiemetic’. Indian Journal of Paediatric Oncology. 2019; 40(2): 274-276.
Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Dietrich MBL, et al. Olanzapine for The Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): Alliance A221301, A Randomized, Double-blind, Placebo-Controlled Trial. American Society of Clinical Oncology. 2015; 33.
Maeda A, Ura T, Asano C, Haegawa I, Nomura M, Komori A, et al. A Phase II Trial of Prophylactic Olanzapine Combined with Palonosetron and Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin. Asia-Pacific Journal of Clinical Oncology. 2016; 12(3): 254-258.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2017; 35(28): 3240-3261.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, Version 1.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed Mar 18, 2020.
Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y. Olanzapine-Containing Antiemetic Therapy for The Prevention of Carboplatin-Induced Nausea and Vomiting. Cancer Chemotherapy and Pharmacology. 2019; 84: 147-153.
Muench J, and Hamer AM. Adverse Effects of Antipsychotic Medications. American Family Physician. 2010; 81(5): 617-622.
Kaneishi K, Kawabata M, Morita T. Olanzapine for The Relief of Nausea in Patients With Advanced Cancer and Incomplete Bowel Obstruction. Journal of Pain Symptom and Management. 2012; 44(4): 604‐607.
Alldredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., Williams, B.R. Editors. Applied Therapeutics: The Clinical Use of Drugs. Philadelphia: Lippincott Williams & Wilkins. 2013; 10th Ed: p. 106.
MacKintosh D. Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series. Journal of Palliative Medicine. 2016; 19(1): 87‐90.
Navari RM. Editor. Management of Chemotherapy-Induced Nausea and Vomiting New Agents and New Uses of Current Agents. Unites State: Springer International Publishing Switzerland. 2016; pp. 118.
Katzung BG, Kruidering-Hall M, Trevor AJ. Editors. Katzung & Trevor’s Pharmacology Examination & Board Review. United States: McGraw-Hill Education. 2019; 12th Ed: pp. 243-244.
Kast RE, and Foley KF. Cancer Chemotherapy and Cachexia: Mirtazapine and Olanzapine are 5-HT3 Antagonists with Good Antinausea Effects. European Journal of Cancer Care. 2007; 16: 351‐354.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and Cardiovascular Adverse Effects Associated with Antipsychotic Drugs. Nature Reviews Endocrinology. 2012; 8(2): 114-126.
Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Editors. Harrison’s Principles of Internal Medicine. United States: McGraw-Hill Education. 2015; 19th Ed: pp. 64.
Hou PH, Chang GR, Chen CP, Lin YL, Chao IS, Shen TT, Mao FC. Long-Term Administration of Olanzapine Induces Adiposity and Increases Hepatic Fatty Acid Desaturation Protein in Female C57BL/6J Mice. Iranian Journal of Basic Medical Sciences. 2018; 21(5): 495-501.
Meyer JM, and Stahl SM. The Metabolic Syndrome and Schizophrenia. Acta Psychiatrica Scandinavica. 2009; 119(1): 4-14.
Huang M, Yu L, Pan F, Lu S, Hu S, Hu J, et al. A Randomized, 13-Week Study Assessing The Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018; 81: 122-130.
Li R, Ou J, Li L, Yang Y, Zhao J, Wu R. The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance. Frontiers in Pharmacology. 2018; 9: 379.
Nicol GE, Yingling MD, Flavin KS, Schweiger JA, Patterson BW, Schechtman KB, Newcomer JW. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. JAMA Psychiatry. 2018; 75(8): 788-796.
Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An Integrated Analysis of Acute Treatment-Emergent Extrapyramidal Syndrome in Patients with Schizophrenia during Olanzapine Clinical Trials: Comparisons with Placebo, Haloperidol, Risperidone, or Clozapine. Journal of Clinical Psychiatry. 2003; 64(8): 898-906.
Papadakis M, McPhee SJ, Rabow MW. Editors. Current Medical Diagnosis & Treatment. United States: McGraw-Hill Education. 2015; 54th Ed: pp. 1046.
Whalen K, Finkel R, Panavelil TA. Editors. Illustrated Reviews: Pharmacology. Philadelphia: Wolters Kluwer. 2015; 6th Ed: pp. 146-147.
Tollens F, Gass N, Becker R, Schwarz AJ, Risterucci C, Künnecke B, et al. The Affinity of Antipsychotic Drugs to Dopamine and Serotonin 5-HT2 receptors Determines Their Effects on Prefrontal-Striatal Functional Connectivity. European Neuropsychopharmacol. 2018; 28(9): 1035-1046.
Morita T, Tei Y, Shishido H, Inoue S. Olanzapine-Induced Delirium in A Terminally Ill Cancer Patient. Journal of Pain Symptom Management. 2004; 28: 102-103.
Kim HM, Chiang C, Kales HC. After The Black Box Warning: Predictors of Psychotropic Treatment Choices for Older Patients with Dementia. Psychiatric Services. 2011; 62(10): 1207-1214.
Yeo W, Lau TKH, Li L, Lai KT, Pang E, Cheung M, et al. A Randomized Study of Olanzapine-Containing versus Standard Antiemetic Regimens for The Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients. The Breast. 2020; 50: 30-3
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish their manuscripts in this journal agree to the following conditions:
- The copyright on each article belongs to the author(s).
- The author acknowledges that the International Journal of Advanced Multidisciplinary (IJAM) has the right to be the first to publish with a Creative Commons Attribution 4.0 International license (Attribution 4.0 International (CC BY 4.0).
- Authors can submit articles separately, arrange for the non-exclusive distribution of manuscripts that have been published in this journal into other versions (e.g., sent to the author's institutional repository, publication into books, etc.), by acknowledging that the manuscript has been published for the first time in the International Journal of Advanced Multidisciplinary (IJAM).
